AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD
Phase 4
Completed
- Conditions
- Gastroesophageal Reflux Disease
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2009-03-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 90
- Registration Number
- NCT00410592
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico
🇺🇸Research SIte, Chapel Hill, North Carolina, United States
Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)
Phase 4
Completed
- Conditions
- Asthma
- Interventions
- Drug: Usual Care Inhaled Glucocorticosteroids
- First Posted Date
- 2006-11-28
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1121
- Registration Number
- NCT00404547
- Locations
- 🇨🇦
"Altana Pharma/Nycomed", York, Canada
A Study to Examine the Safety, Tolerability, and Body Weight Effect of Pramlintide Alone and in Combination With Oral Antiobesity Agents in Overweight and Obese Subjects
Phase 2
Completed
- Conditions
- OverweightObesity
- Interventions
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 258
- Registration Number
- NCT00402077
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
Efficacy and Safety Study of Esomeprazole 20mg qd vs Ranitidine 150mg Bid in Patients With an NSAID-induced Gastric Ulcer
Phase 3
Completed
- Conditions
- Gastric Ulcer
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2010-07-08
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 397
- Registration Number
- NCT00401752
- Locations
- 🇭🇰
Research Site, Hong Kong, Hong Kong
Efficacy and Safety Study of Esomeprazole vs Omeprazole to Treat Acute Non-Variceal Upper Gastrointestinal Bleeding
Phase 3
Completed
- Conditions
- Gastrointestinal Hemorrhage
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2009-03-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 440
- Registration Number
- NCT00402259
- Locations
- 🇨🇳
Research Site, Tianjin, China
🇨🇳Research site, Fuzhou, Fujian, China
Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer
Phase 3
Completed
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)Drug: XELOX (Capecitabine and Oxaliplatin)
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2016-12-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1254
- Registration Number
- NCT00399035
- Locations
- 🇬🇧
Research Site, Manchester, United Kingdom
ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
Phase 4
Withdrawn
- Conditions
- Primary Hypercholesterolaemia
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1294
- Registration Number
- NCT00396240
Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)
Completed
- Conditions
- HypercholesterolemiaCoronary Heart Disease
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2006-11-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 3889
- Registration Number
- NCT00396110
ROMEO (Rosuvastatin in Metabolic syndrOme)
- First Posted Date
- 2006-11-03
- Last Posted Date
- 2011-07-11
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 258
- Registration Number
- NCT00395486
- Locations
- 🇰🇷
Research Site, Suwon, Korea, Republic of
Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients
Phase 2
Completed
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2013-03-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 244
- Registration Number
- NCT00394472
- Locations
- 🇷🇴
Research Site, Targu Mures, Romania
© Copyright 2025. All Rights Reserved by MedPath